Efficacy of alternative fidaxomicin dosing regimens for treatment of simulatedClostridium difficileinfection in anin vitrohuman gut model

Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials

(2014) Stuart Johnson et al.   CLINICAL INFECTIOUS DISEASES

Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies

(2014) M. M. Soriano et al.   Open Forum Infectious Diseases

ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients

(2013) E. Tacconelli et al.   CLINICAL MICROBIOLOGY AND INFECTION

In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection

(2013) C. H. Chilton et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure

(2013) C. H. Chilton et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI

(2012) T. J. Louie et al.   CLINICAL INFECTIOUS DISEASES

Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

(2012) Derrick W. Crook et al.   CLINICAL INFECTIOUS DISEASES

Can we identify patients at high risk of recurrent Clostridium difficile infection?

(2012) C.P. Kelly   CLINICAL MICROBIOLOGY AND INFECTION

Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection

(2012) G. S. Crowther et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection

(2012) P.N. Wiegand et al.   JOURNAL OF HOSPITAL INFECTION

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

(2012) Oliver A Cornely et al.   LANCET INFECTIOUS DISEASES

Postantibiotic Effect of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium difficile

(2011) Farah Babakhani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of the Burdens of Hospital-Onset, Healthcare Facility-Associated Clostridium difficile Infection and of Healthcare-Associated Infection due to Methicillin-Resistant Staphylococcus aureus in Community Hospitals

(2011) Becky A. Miller et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Economic healthcare costs of Clostridium difficile infection: a systematic review

(2010) S.S. Ghantoji et al.   JOURNAL OF HOSPITAL INFECTION

Clostridium difficile infection in Europe: a hospital-based survey

(2010) Martijn P Bauer et al.   LANCET

A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin

(2010) G. W. Tannock et al.   MICROBIOLOGY-SGM

Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes

(2009) Stuart Johnson   JOURNAL OF INFECTION

Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model

(2008) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY